JP2021195357A - Urine concentration promoter - Google Patents
Urine concentration promoter Download PDFInfo
- Publication number
- JP2021195357A JP2021195357A JP2020105342A JP2020105342A JP2021195357A JP 2021195357 A JP2021195357 A JP 2021195357A JP 2020105342 A JP2020105342 A JP 2020105342A JP 2020105342 A JP2020105342 A JP 2020105342A JP 2021195357 A JP2021195357 A JP 2021195357A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- urine
- extract
- parts
- renko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 40
- 240000002853 Nelumbo nucifera Species 0.000 claims description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 241000411851 herbal medicine Species 0.000 abstract description 7
- 230000035619 diuresis Effects 0.000 abstract description 4
- 230000035622 drinking Effects 0.000 description 17
- 239000000843 powder Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 241001127637 Plantago Species 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 240000004534 Scutellaria baicalensis Species 0.000 description 8
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 206010029446 nocturia Diseases 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 206010036018 Pollakiuria Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000005156 Dehydration Diseases 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940018492 plantago seed Drugs 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- -1 brighteners Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
Description
本発明は、尿濃縮促進剤に関する。 The present invention relates to a urine concentration promoter.
尿に関する問題として、多尿と頻尿とがあり、それぞれの確定診断法が確立されている。臨床上の多尿及び頻尿いずれについても、症状として、夜間の排尿の回数が増える夜間頻尿が含まれる可能性がある（非特許文献１）。 There are polyuria and pollakiuria as problems related to urine, and definitive diagnostic methods for each have been established. For both clinical polyuria and pollakiuria, nocturia, which increases the frequency of nocturia at night, may be included as a symptom (Non-Patent Document 1).
多尿は、１日尿量が３リットルを超える症状と定義され、さらに、水そのものが多い場合（水利尿）と、溶質が多い場合（浸透圧利尿）に大きく分けられ、それらの確定診断法も確立されている（非特許文献２）。前者の代表的疾患が尿崩症であり、後者の代表的疾患が糖尿病である。いずれの場合も口渇を伴い、多尿は口渇の亢進により維持される。これらの症状の鑑別方法としては、尿比重が１．００７より低い場合に水利尿、１．０２５より高い場合に浸透圧利尿と鑑別する方法が挙げられ、より正確を期すには尿の浸透圧を測定することができる（非特許文献２）。 Polyuria is defined as a symptom in which the daily urine volume exceeds 3 liters, and is further divided into cases where there is a large amount of water itself (hydraulic urine) and cases where there is a large amount of solute (osmotic diuresis). Has also been established (Non-Patent Document 2). The representative disease of the former is diabetes insipidus, and the representative disease of the latter is diabetes. In both cases, dry mouth is associated and polyuria is maintained by increased dry mouth. Examples of the method for differentiating these symptoms include irrigation when the specific gravity of urine is lower than 1.007 and osmotic diuresis when the specific gravity is higher than 1.025. Can be measured (Non-Patent Document 2).
多尿への対処として、生活指導が多く行われている。これは、問診などにより過剰な飲水を行っていることが多尿の原因だと分かることが少なくないためである（非特許文献３）。高齢者は脱水症になりやすいため注意を要するが、脱水状態にない人には飲水過多を避ける指導がなされる。実際の指導として、１日の飲水量は体重の２〜２．５％を指導するのが適当とされている（非特許文献４）。 Life guidance is often given to deal with polyuria. This is because it is often found that excessive drinking of water is the cause of polyuria through interviews (Non-Patent Document 3). Elderly people are prone to dehydration, so caution is required, but those who are not dehydrated are instructed to avoid excessive drinking. As an actual instruction, it is appropriate to instruct the daily drinking amount of 2 to 2.5% of the body weight (Non-Patent Document 4).
一方、頻尿では、膀胱の膀胱平滑筋が過剰に収縮している状態にあるため貯められる尿量が減少し、その結果、急な尿意を感じる、トイレの回数が増える、我慢できなくなるなど様々な排尿トラブルを引き起こす（非特許文献５）。また、膀胱は、尿を貯め、尿量が適当量になった場合に収縮すると同時に尿道括約筋が弛緩するという複雑な神経支配に依存するため、頻尿は、このような神経の疾患（膀胱神経症）に付随することも少なくない（非特許文献２）。 Frequent urination, on the other hand, causes the bladder smooth muscle of the bladder to contract excessively, reducing the amount of urine that can be stored. Causes frequent urination troubles (Non-Patent Document 5). Frequent urination is also a neurological disorder (bladder nerve) because the bladder stores urine and relies on a complex innervation of contraction and relaxation of the urethral sphincter when the volume of urine reaches an appropriate level. It is often associated with illness) (Non-Patent Document 2).
臨床上の頻尿への対処として漢方療法が知られており、その一例として、清心蓮子飲が挙げられる。清心蓮子飲については、膀胱平滑筋の収縮を抑制することで頻尿を改善すること（非特許文献５）、及び膀胱神経症に対して１００％の極めて高い改善度が認められたこと（非特許文献６）が確認されている。 Chinese herbal medicine is known as a clinical treatment for pollakiuria, and one example is Seishin Renko-drinking. Regarding Seishin Renko-drinking, frequent urination was improved by suppressing the contraction of bladder smooth muscle (Non-Patent Document 5), and an extremely high degree of improvement of 100% was observed for bladder neurosis (non-patent document 5). Patent Document 6) has been confirmed.
多尿に対しては、根本的に尿の濃縮度を上げる対処が必要であり、飲水過多を避ける指導が主流となっている。しかしながら、高齢者や投薬患者等にとっては、脱水症状を起こすリスクや、脳梗塞・心筋梗塞などのリスクがあり、上記の指導を適切に行うことは困難である。一方、近年の健康意識の高まりと共に、軽度な体調不良は自分で対処するセルフメディケーションへの関心も高まってきていることに鑑みると、多尿への対処手段として漢方薬が利用できることが望ましい。しかしながら、飲水量のコントロールを要さずに尿の濃縮を促進できるような漢方薬は知られていない。なお、清心蓮子飲が臨床上の頻尿に対して適用されてきたが、そのメカニズムは尿道平滑筋の収縮抑制や神経鎮静といったものであり、多尿に対して尿の濃縮を促進できる効果は知られていなかった。 For polyuria, it is necessary to take measures to fundamentally increase the concentration of urine, and guidance to avoid excessive drinking is the mainstream. However, for the elderly and medication patients, there is a risk of dehydration and a risk of cerebral infarction / myocardial infarction, and it is difficult to properly give the above guidance. On the other hand, it is desirable that Chinese herbal medicine can be used as a means of coping with polyuria, considering that with the increase of health consciousness in recent years, there is also increasing interest in self-medication to deal with mild illness by oneself. However, there is no known Chinese herbal medicine that can promote urine concentration without the need to control the amount of drinking water. Although Seishin Renko-drinking has been applied to clinical pollakiuria, its mechanism is to suppress contraction of urethral smooth muscle and nerve sedation, and it has the effect of promoting urinary concentration for polyuria. It was not known.
本発明は、尿の濃縮を促進できる漢方薬を提供することを目的とする。 An object of the present invention is to provide a Chinese herbal medicine capable of promoting the concentration of urine.
本発明者らは、鋭意検討した結果、意外にも、清心蓮子飲に、尿の濃縮を促進できる作用があることを見出した。本発明は、この知見に基づいて、更に検討を重ねることにより完成したものである。 As a result of diligent studies, the present inventors have found that, surprisingly, Seishin Renko drinking has an effect of promoting the concentration of urine. The present invention has been completed by further studies based on this finding.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． 清心蓮子飲エキスを含有する、尿濃縮促進剤。
項２・ 水利尿に用いられる、項１に記載の尿濃縮促進剤。
That is, the present invention provides the inventions of the following aspects.
Item 1. A urine concentration promoter containing a lotus seed extract.
Item 2. The urine concentration promoter according to Item 1, which is used for diuretic urine.
本発明によれば、尿の濃縮を促進できる漢方薬が提供されるため、多尿を改善することが可能となる。 According to the present invention, since a Chinese herbal medicine capable of promoting the concentration of urine is provided, polyuria can be improved.
本発明の尿濃縮促進剤は、清心蓮子飲エキスを含有することを特徴とする。以下、本発明の尿濃縮促進剤について詳述する。 The urine concentration promoter of the present invention is characterized by containing a lotus seed extract. Hereinafter, the urine concentration accelerator of the present invention will be described in detail.
有効成分
本発明の尿濃縮促進剤は、清心蓮子飲エキスを含有する。清心蓮子飲は、中国明時代の医書「万病回春」に記載されており、レンニク、バクモンドウ、ブクリョウ、ニンジン、シャゼンシ、オウゴン、オウギ、ジコッピ、カンゾウを含む混合生薬である。
Active Ingredient The urine concentration accelerator of the present invention contains a Seishin Renko drinking extract. Scutellaria baicalensis is a mixed herbal medicine containing lotus seeds, scutellaria baicalensis, scutellaria baicalensis, scutellaria baicalensis, scutellaria baicalensis, scutellaria baicalensis, scutellaria baicalensis, scutellaria baicalensis, and licorice.
本発明において、清心蓮子飲を構成する生薬の混合比については特に制限されないが、通常、レンニク２〜５重量部、好ましくは３〜４重量部；バクモンドウ１．５〜４重量部、好ましくは２〜３重量部；ブクリョウ２〜４重量部、好ましくは２．５〜３．５重量部；ニンジン１．５〜５重量部、好ましくは２〜４重量部；シャゼンシ１．５〜３重量部、好ましくは２〜２．５重量部；オウゴン１．５〜３重量部、好ましくは２〜２．５重量部；オウギ１〜４重量部、好ましくは２〜３重量部；ジコッピ１〜３重量部、好ましくは２〜２．５重量部；カンゾウ０．７〜２重量部、好ましくは０．７〜１重量部が挙げられる。 In the present invention, the mixing ratio of the raw medicines constituting the plantago seed drink is not particularly limited, but usually 2 to 5 parts by weight, preferably 3 to 4 parts by weight of plantago seeds; 1.5 to 4 parts by weight of plantago seeds, preferably 2 parts by weight. ~ 3 parts by weight; 2-4 parts by weight, preferably 2.5-3.5 parts by weight; 1.5-5 parts by weight of carrots, preferably 2-4 parts by weight; 1.5-3 parts by weight of plantago seeds, Preferably 2 to 2.5 parts by weight; 1.5 to 3 parts by weight of plantago seeds, preferably 2 to 2.5 parts by weight; 1 to 4 parts by weight of plantago seeds, preferably 2 to 3 parts by weight; 1 to 3 parts by weight of plantago seeds. , Preferably 2 to 2.5 parts by weight; 0.7 to 2 parts by weight of plantago seeds, preferably 0.7 to 1 part by weight.
本発明で使用される清心蓮子飲エキスの製造に供される生薬調合物の好適な例としては、レンニク３．５重量部、バクモンドウ２．１重量部、ブクリョウ２．８重量部、ニンジン３．５重量部、シャゼンシ２．１重量部、オウゴン２．１重量部、オウギ２．８重量部、ジコッピ２．１重量部、カンゾウ０．７重量部が挙げられる。 Suitable examples of the crude drug formulation used in the production of the plantago seed drink extract used in the present invention are 3.5 parts by weight of plantago seeds, 2.1 parts by weight of Bakumondou, 2.8 parts by weight of Bukuryo, and 3. Examples include 5 parts by weight, 2.1 parts by weight of plantago seeds, 2.1 parts by weight of Ogon, 2.8 parts by weight of Ougi, 2.1 parts by weight of Jikoppi, and 0.7 parts by weight of Kanzo.
清心蓮子飲のエキスの形態としては、流エキス、軟エキス等の液状のエキス、又は固形状の乾燥エキス末のいずれであってもよい。 The form of the extract of Seishin Renko-drink may be any of a liquid extract such as a flow extract and a soft extract, or a solid dry extract powder.
清心蓮子飲の液状のエキスは、清心蓮子飲に従った混合生薬を抽出処理し、得られた抽出液を必要に応じて濃縮することにより得ることができる。抽出処理に使用される抽出溶媒としては、特に限定されず、水又は含水エタノール、好ましくは水が挙げられる。また、清心蓮子飲の乾燥エキス末は、液状のエキスを乾燥処理することにより得ることができる。乾燥処理の方法としては特に限定されず、例えば、スプレードライ法や、エキスの濃度を高めた軟エキスに適当な吸着剤（例えば無水ケイ酸、デンプン等）を加えて吸着末とする方法等が挙げられる。 The liquid extract of Seishin Renko Drink can be obtained by extracting and treating the mixed crude drug according to Seishin Renko Drink and concentrating the obtained extract as necessary. The extraction solvent used in the extraction treatment is not particularly limited, and examples thereof include water or hydrous ethanol, preferably water. In addition, the dried extract powder of Seishin Renko Drink can be obtained by drying the liquid extract. The method of the drying treatment is not particularly limited, and for example, a spray-drying method, a method of adding an appropriate adsorbent (for example, anhydrous silicic acid, starch, etc.) to a soft extract having an increased concentration of the extract to obtain an adsorbed powder, and the like are used. Can be mentioned.
本発明において、清心蓮子飲エキスとしては、前述の方法で調製したエキスを使用してもよいし、市販されるものを使用してもよい。例えば、清心蓮子飲の乾燥エキス末としては、清心蓮子飲乾燥エキス−Ｑ（日本粉末薬品株式会社製）、清心蓮子飲乾燥エキス−Ｆ（アルプス薬品株式会社製）等が商品として知られており、商業的に入手することもできる。 In the present invention, as the Seishin Renko drinking extract, the extract prepared by the above-mentioned method may be used, or a commercially available one may be used. For example, as the dried extract powder of Seishin Renko Drink, Seishin Renko Drinking Dry Extract-Q (manufactured by Nippon Powder Pharmaceutical Co., Ltd.), Seishin Renko Drinking Dry Extract-F (manufactured by Alps Pharmaceutical Co., Ltd.), etc. are known as products. , Also available commercially.
本発明の尿濃縮促進剤において、清心蓮子飲エキスの含有量としては、本発明の効果を奏する限り、特に限定されないが、清心蓮子飲エキスの乾燥エキス末量換算で、通常１０〜１００重量％、好ましくは２０〜９０重量％、より好ましくは４０〜８０重量％、更に好ましくは６０〜７０重量％が挙げられる。なお、本発明において、清心蓮子飲の乾燥エキス末量換算とは、清心蓮子飲の乾燥エキス末を使用する場合にはそれ自体の量であり清心蓮子飲の液状のエキスを使用する場合には、溶媒を除去した残量に換算した量である。また、清心蓮子飲の乾燥エキス末が、製造時に添加される吸着剤等の添加剤を含む場合は、当該添加剤を除いた量である。 In the urine concentration accelerator of the present invention, the content of the Seishin Renko drinking extract is not particularly limited as long as the effect of the present invention is exhibited, but it is usually 10 to 100% by weight in terms of the dry extract powder amount of the Seishin Renko drinking extract. , Preferably 20 to 90% by weight, more preferably 40 to 80% by weight, still more preferably 60 to 70% by weight. In the present invention, the dry extract powder conversion of Seishin Renko Drink is the amount itself when the dried extract powder of Seishin Renko Drink is used, and when the liquid extract of Seishin Renko Drink is used, it is the amount itself. , The amount converted to the remaining amount after removing the solvent. When the dried extract powder of Seishin Renko Drink contains an additive such as an adsorbent added at the time of production, the amount is the amount excluding the additive.
その他の成分
本発明の尿濃縮促進剤は、清心蓮子飲エキス単独からなるものであってもよく、製剤形態に応じた添加剤や基剤を含んでいてもよい。このような添加剤及び基剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、等張化剤、可塑剤、分散剤、乳化剤、溶解補助剤、湿潤化剤、安定化剤、懸濁化剤、粘着剤、コーティング剤、光沢化剤、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、金属石鹸、低級アルコール類、多価アルコール、ｐＨ調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、矯味剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの添加剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、これらの添加剤及び基剤の含有量については、使用する添加剤及び基剤の種類、尿濃縮促進剤の製剤形態等に応じて適宜設定される。
Other Ingredients The urine concentration-promoting agent of the present invention may consist of the Seishin Renko drinking extract alone, or may contain additives and bases according to the pharmaceutical form. Such additives and bases are not particularly limited as long as they are pharmaceutically acceptable, but for example, excipients, binders, disintegrants, lubricants, tonicity agents, plasticizers, etc. Dispersants, emulsifiers, solubilizers, wetting agents, stabilizers, suspending agents, pressure-sensitive agents, coating agents, brighteners, water, fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols , Esters, water-soluble polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH regulators, buffers, antioxidants, UV inhibitors, preservatives, emulsifiers, fragrances, powders, Examples include thickeners, pigments, chelating agents and the like. These additives may be used alone or in combination of two or more. The contents of these additives and bases are appropriately set according to the types of additives and bases to be used, the pharmaceutical form of the urine concentration accelerator, and the like.
また、本発明の尿濃縮促進剤は、清心蓮子飲エキスの他に、必要に応じて、他の栄養成分や薬理成分を含有していてもよい。このような栄養成分や薬理成分としては、薬学的に許容されることを限度として特に制限されないが、例えば、制酸剤、健胃剤、消化剤、整腸剤、鎮痙剤、粘膜修復剤、抗炎症剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、鎮静催眠剤、抗ヒスタミン剤、カフェイン類、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、生薬エキス、ビタミン類、メントール類等が挙げられる。これらの栄養成分や薬理成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、これらの成分の含有量については、使用する成分の種類等に応じて適宜設定される。 Further, the urine concentration accelerator of the present invention may contain other nutritional components and pharmacological components, if necessary, in addition to the Seishin Renko drinking extract. Such nutritional components and pharmacological components are not particularly limited as long as they are pharmaceutically acceptable, but for example, antacids, stomachic agents, digestive agents, intestinal regulators, antispasmodics, mucosal repair agents, anti-inflammatory agents, and astringents. Agents, antiemetics, antitussives, sputum, anti-inflammatory enzyme agents, sedative hypnotics, antihistamines, caffeines, cardiotonic diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, crude drug extracts, vitamins, menthol Kind and the like. These nutritional components and pharmacological components may be used alone or in combination of two or more. Further, the content of these components is appropriately set according to the type of the component to be used and the like.
製剤形態
本発明の尿濃縮促進剤の製剤形態については、経口投与が可能であることを限度として特に制限されないが、例えば、散剤、細粒剤、顆粒剤、錠剤、トローチ剤、チュアブル剤、カプセル剤（軟カプセル剤、硬カプセル剤）、丸剤等の固形状製剤；ゼリー剤等の半固形状製剤；液剤、懸濁剤、シロップ剤等の液状製剤が挙げられ、好ましくは顆粒剤又は錠剤が挙げられる。
Formulation form The formulation form of the urine concentration-promoting agent of the present invention is not particularly limited as long as it can be orally administered, and is, for example, a powder, a fine granule, a granule, a tablet, a troche, a chewable agent, or a capsule. Examples include solid formulations such as agents (soft capsules and hard capsules) and rounds; semi-solid formulations such as jelly; liquid formulations such as liquids, suspending agents and syrups, preferably granules or tablets. Can be mentioned.
製造方法
本発明の尿濃縮促進剤の製造方法は、上記生薬成分を用いて、医薬分野で採用されている通常の製剤化手法に従って製剤化すればよい。
Production method The method for producing the urine concentration accelerator of the present invention may be formulated by using the above-mentioned crude drug components according to a usual formulation method adopted in the pharmaceutical field.
用途
本発明の尿濃縮促進剤は、尿の濃縮を促進する目的で使用される。尿の濃縮促進を要する症状としては、具体的には多尿が挙げられる。多尿とは、臨床上、１日尿量が３リットルを超える症状と定義される。多尿には、水そのものが多い症状（臨床上、水利尿と称され、例えば尿崩症が挙げられる。）と、溶質が多い症状（臨床上、浸透圧利尿と称され、例えば糖尿病が挙げられる。）とが挙げられ、これらの症状は確定診断法が確立されており、いずれも尿が薄い点で共通している。これらの症状の中でも、本発明の尿濃縮促進剤は、水利尿に好ましく適用される。
Uses The urine concentration promoter of the present invention is used for the purpose of promoting urine concentration. Specific examples of the symptom requiring promotion of urine concentration include polyuria. Polyuria is clinically defined as a symptom with a daily urine output of more than 3 liters. Polyuria includes a symptom with a large amount of water itself (clinically referred to as hydrodiuresis, for example, diabetes insipidus) and a symptom with a large amount of solute (clinically referred to as osmotic diuresis, for example, diabetes). ), And these symptoms have established definitive diagnostic methods, all of which are common in that urine is thin. Among these symptoms, the urine concentration promoter of the present invention is preferably applied to aquatic urine.
また、本発明の尿濃縮促進剤は、過飲水（１日の飲水量が体重の２．５％を超えること）でありながら、飲水量のコントロールが困難である人、たとえば脱水状態が起きやすい人、より具体的には体内に水分をためにくい高齢者（具体的には６５歳以上）、降圧薬等の利尿作用のある薬を服用している人等に対しても好ましく適用される。 In addition, the urine concentration promoter of the present invention is prone to dehydration, for example, for people who have difficulty in controlling the amount of water they drink, even though they are overdrinking (the amount of water they drink per day exceeds 2.5% of their body weight). It is also preferably applied to humans, more specifically elderly people (specifically, 65 years old or older) who have difficulty storing water in the body, and people who are taking diuretic drugs such as antihypertensive drugs.
用量・用法
本発明の尿濃縮促進剤は、経口投与によって使用される。本発明の尿濃縮促進剤の用量については、投与対象者の年齢、体質、症状の程度等に応じて適宜設定されるが、例えば、ヒトに対して１日当たり、清心蓮子飲エキスの乾燥エキス末量換算で１５００〜５０００ｍｇ程度、好ましくは２０００〜３０００ｍｇ程度、より好ましくは２２００〜２５００ｍｇ程度となる量で、１日１〜３回、好ましくは２回の頻度で服用すればよい。服用タイミングについては、特に制限されず、食前、食後、又は食間のいずれであってもよいが、食前（食事の３０分前）又は食間（食後２時間後）が好ましい。
Dosage and Usage The urine concentration promoter of the present invention is used by oral administration. The dose of the urine concentration promoter of the present invention is appropriately set according to the age, constitution, degree of symptoms, etc. of the subject to be administered. It may be taken in an amount of about 1500 to 5000 mg, preferably about 2000 to 3000 mg, more preferably about 2200 to 2500 mg, 1 to 3 times a day, preferably 2 times a day. The timing of administration is not particularly limited and may be before meals, after meals, or between meals, but it is preferably before meals (30 minutes before meals) or between meals (2 hours after meals).
また、本発明の尿濃縮促進剤による尿濃縮の促進効果は、継続的な服用によって奏されるので、本発明の尿濃縮促進剤は、継続的な服用（具体的には１週間以上、好ましくは２週間以上の継続的な服用）を行うことが好ましい。 Further, since the urine concentration promoting effect of the urine concentration promoting agent of the present invention is exerted by continuous administration, the urine concentration promoting agent of the present invention is preferably taken continuously (specifically, for one week or more, preferably for one week or more). It is preferable to take it continuously for 2 weeks or more.
以下、本発明を実施例により具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is not limited to these Examples.
（１）尿濃縮促進剤の調製
原料生薬として、レンニク３．５重量部、バクモンドウ２．１重量部、ブクリョウ２．８重量部、ニンジン３．５重量部、シャゼンシ２．１重量部、オウゴン２．１重量部、オウギ２．８重量部、ジコッピ２．１重量部、カンゾウ０．７重量部を用い、これらを刻んだ後、水１０倍重量を用いて約１００℃で１時間抽出し、遠心分離して抽出液を得た。抽出液を減圧下で濃縮してスプレードライヤーを用いて乾燥し、清心蓮子飲エキス末を得た。得られた清心蓮子飲エキス末は、原料生薬混合物２１．７ｇ当たり２２３８ｍｇであった。なお、スプレードライヤーによる乾燥は、抽出液を回転数１００００ｒｐｍのアトマイザーに落下させ、１５０℃の空気の熱風を供給して行った。
(1) Preparation of urine concentration accelerator As raw material raw medicine, 3.5 parts by weight of Rennik, 2.1 parts by weight of Bakumondou, 2.8 parts by weight of Bukuryo, 3.5 parts by weight of carrot, 2.1 parts by weight of plantago seed, Ogon 2 .1 part by weight, 2.8 parts by weight of ougi, 2.1 parts by weight of plantago seeds, 0.7 parts by weight of plantago seeds were used, and after chopping them, they were extracted at about 100 ° C. for 1 hour using 10 times the weight of water. The extract was obtained by centrifugation. The extract was concentrated under reduced pressure and dried using a spray dryer to obtain Seishin Renko drinking extract powder. The obtained Seishin Renko drinking extract powder was 2238 mg per 21.7 g of the raw material crude drug mixture. The drying with a spray dryer was carried out by dropping the extract onto an atomizer having a rotation speed of 10000 rpm and supplying hot air with air at 150 ° C.
（２）実験方法
実験動物として高齢マウス（Ｃ５７ＢＬ／６Ｊマウス、８０週齢、雄、２０匹）を使用した。このマウスは、若齢マウス（Ｃ５７ＢＬ／６Ｊマウス、９週齢、雄）に比べて飲水量が多いことを確認し、過飲水モデルとして使用した。この高齢マウスをコントロール群と清心蓮子エキス飲投与群と（それぞれＮ＝１０）に分けた。コントロール群に対しては通常食（ＣＥ−２餌）を自由摂食させて３週間飼育し、清心蓮子飲エキス投与群には、当該通常食に４重量％の清心蓮子飲エキスを混ぜた餌を自由摂食させて３週間飼育した。それぞれの群に関して、試験前と試験後に尿を採取し、尿濃度（比重及び浸透圧）を測定した。結果を表１に示す。
(2) Experimental method Aged mice (C57BL / 6J mice, 80 weeks old, male, 20 animals) were used as experimental animals. It was confirmed that this mouse had a larger amount of drinking water than a young mouse (C57BL / 6J mouse, 9 weeks old, male), and was used as an overdrinking model. The aged mice were divided into a control group and a Seishin Renko extract drinking group (N = 10 respectively). The control group was fed a normal diet (CE-2 diet) freely and bred for 3 weeks, and the group to which the Seishin Renko drinking extract was administered was a diet in which 4% by weight of the Seishin Renko drinking extract was mixed. Was fed freely and bred for 3 weeks. For each group, urine was collected before and after the test and the urine concentration (density and osmotic pressure) was measured. The results are shown in Table 1.
表１に示す通り、清心蓮子飲エキス投与群では浸透圧の大幅な上昇、および比重の増加が認められており、清心蓮子飲エキスの投与によって、尿の濃縮が促進されたことが認められた。 As shown in Table 1, a significant increase in osmotic pressure and an increase in specific density were observed in the Seishin Renko drinking extract administration group, and it was confirmed that the administration of Seishin Renko drinking extract promoted the concentration of urine. ..
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020105342A JP2021195357A (en) | 2020-06-18 | 2020-06-18 | Urine concentration promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020105342A JP2021195357A (en) | 2020-06-18 | 2020-06-18 | Urine concentration promoter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021195357A true JP2021195357A (en) | 2021-12-27 |
Family
ID=79197090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020105342A Pending JP2021195357A (en) | 2020-06-18 | 2020-06-18 | Urine concentration promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2021195357A (en) |
-
2020
- 2020-06-18 JP JP2020105342A patent/JP2021195357A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06500313A (en) | Drugs, their production and their use in suppressing pain and/or inflammation in animals and humans | |
| KR100594400B1 (en) | Treatment of spasticity, convulsions by isovaleric acid derivatives cns depressants | |
| WO1998008498A9 (en) | Treatment of spasticity, convulsions by isovaleric acid derivatives cns depressants | |
| CN100518775C (en) | Medicine composition for treating cough and asthma and preparation thereof | |
| JP2021195357A (en) | Urine concentration promoter | |
| CN101380452A (en) | Preparation method of no-alcohol type Shexiang Qushu liquid oral preparation | |
| JP2006514041A (en) | Composition for suppressing obesity using mixed herbal materials | |
| JP4049406B2 (en) | Tsu fluid improving agent and composition for oral administration containing the same | |
| JP2021195358A (en) | Kidney function improving agent | |
| JP4950551B2 (en) | Gastrointestinal mucosa protective agent | |
| CN114903960B (en) | Traditional Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| JP2021102603A (en) | Stress urinary incontinence improver | |
| JP2022022617A (en) | Muscle synthesis promoter | |
| JP2022011232A (en) | Agent for suppressing protein synthesis inhibition | |
| JP2021119126A (en) | Obesity improver | |
| TWI784169B (en) | Prevention or improvement agent for nocturnal frequent urination | |
| JP2022000423A (en) | Fat in feces discharge promoter | |
| Fors | Herbs for horses | |
| JP2021187801A (en) | Lipid excretion promoter | |
| JP2021119125A (en) | Appetite-regulating hormone secretion normalizing agent | |
| JP2021187803A (en) | Agent for improving cheilitis | |
| JP7408280B2 (en) | Alcohol metabolism improver | |
| JP2022098251A (en) | Premenstrual constipation improver | |
| JP2021104952A (en) | Fibrogenesis inhibitor | |
| JP2022007332A (en) | Kampo preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230529 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |